Bayer cuts its losses on new Betaferon

You win some, you lose some. Bayer is abandoning plans to launch a bigger dose of its multiple sclerosis treatment Betaferon. An internal study found that the 500 mcg dose wasn't any more effective than the already-on-the-market 250 mcg dose, nor was it better than Copaxone, the MS drug made by Teva. Bayer won't ask regulators for approval to sell the new strength, and it's taking a $218.6 million charge against third-quarter earnings as a result.

The BEYOND study did have one bit of good news in it: Fewer patients taking the 250 mcg dose of Betaferon dropped out because of side effects. The drop-out rate for that drug was just 13 percent, compared with 17 percent for Copaxone.

- see Bayer's release on the study
- read the article from the International Herald Tribune

Virtual Clinical Trials Summit

Virtual Clinical Trials Summit: The Premier Educational Event Focused on Decentralized Clinical Trials

In this virtual environment, we will look at current and future trends for ongoing virtual trials, diving into the many ways companies can improve patient engagement and trial behavior to enhance retention with a focus on emerging technology and harmonized data access across the clinical trial system.